Targeted Delivery of Nerve Growth Factor to the Cholinergic Basal Forebrain of Alzheimer's Disease Patients: Application of a Second-generation Encapsulated Cell Biodelivery Device

Overview

Journal Alzheimers Res Ther

Date 2016 Jul 9

PMID 27389402

Citations 60

Authors

Helga Eyjolfsdottir

Maria Eriksdotter

Bengt Linderoth

Goran Lind

Bengt Juliusson

Philip Kusk

Ove Almkvist

Niels Andreasen

Kaj Blennow

Daniel Ferreira

Eric Westman

Inger Nennesmo

Azadeh Karami

Taher Darreh-Shori

Ahmadul Kadir

Agneta Nordberg

Erik Sundstrom

Lars-Olof Wahlund

Anders Wall

Maria Wiberg

Bengt Winblad

Ake Seiger

Lars Wahlberg

Per Almqvist

Affiliations

Soon will be listed here.

Abstract

Background: Targeted delivery of nerve growth factor (NGF) has emerged as a potential therapy for Alzheimer's disease (AD) due to its regenerative effects on basal forebrain cholinergic neurons. This hypothesis has been tested in patients with AD using encapsulated cell biodelivery of NGF (NGF-ECB) in a first-in-human study. We report our results from a third-dose cohort of patients receiving second-generation NGF-ECB implants with improved NGF secretion.

Methods: Four patients with mild to moderate AD were recruited to participate in an open-label, phase Ib dose escalation study with a 6-month duration. Each patient underwent stereotactic implant surgery with four NGF-ECB implants targeted at the cholinergic basal forebrain. The NGF secretion of the second-generation implants was improved by using the Sleeping Beauty transposon gene expression technology and an improved three-dimensional internal scaffolding, resulting in production of about 10 ng NGF/device/day.

Results: All patients underwent successful implant procedures without complications, and all patients completed the study, including implant removal after 6 months. Upon removal, 13 of 16 implants released NGF, 8 implants released NGF at the same rate or higher than before the implant procedure, and 3 implants failed to release detectable amounts of NGF. Of 16 adverse events, none was NGF-, or implant-related. Changes from baseline values of cholinergic markers in cerebrospinal fluid (CSF) correlated with cortical nicotinic receptor expression and Mini Mental State Examination score. Levels of neurofilament light chain (NFL) protein increased in CSF after NGF-ECB implant, while glial fibrillary acidic protein (GFAP) remained stable.

Conclusions: The data derived from this patient cohort demonstrate the safety and tolerability of sustained NGF release by a second-generation NGF-ECB implant to the basal forebrain, with uneventful surgical implant and removal of NGF-ECB implants in a new dosing cohort of four patients with AD.

Trial Registration: ClinicalTrials.gov identifier: NCT01163825 . Registered on 14 Jul 2010.

Citing Articles

Non-Drug and Non-Invasive Therapeutic Options in Alzheimer's Disease.

Sovrea A, Bosca A, Dronca E, Constantin A, Crintea A, Sufletel R Biomedicines. 2025; 13(1).

PMID: 39857667 PMC: 11760896. DOI: 10.3390/biomedicines13010084.

Stimulating myelin restoration with BDNF: a promising therapeutic approach for Alzheimer's disease.

Zota I, Chanoumidou K, Gravanis A, Charalampopoulos I Front Cell Neurosci. 2024; 18:1422130.

PMID: 39285941 PMC: 11402763. DOI: 10.3389/fncel.2024.1422130.

Emerging Pro-neurogenic Therapeutic Strategies for Neurodegenerative Diseases: A Review of Pre-clinical and Clinical Research.

Vassal M, Martins F, Monteiro B, Tambaro S, Martinez-Murillo R, Rebelo S Mol Neurobiol. 2024; 62(1):46-76.

PMID: 38816676 PMC: 11711580. DOI: 10.1007/s12035-024-04246-w.

Polyethersulfone Polymer for Biomedical Applications and Biotechnology.

Wasyleczko M, Wojciechowski C, Chwojnowski A Int J Mol Sci. 2024; 25(8).

PMID: 38673817 PMC: 11049998. DOI: 10.3390/ijms25084233.

The basal forebrain cholinergic system as target for cell replacement therapy in Parkinson's disease.

Bjorklund A, Barker R Brain. 2024; 147(6):1937-1952.

PMID: 38279949 PMC: 11146424. DOI: 10.1093/brain/awae026.

References

Constantinescu R, Holmberg B, Rosengren L, Corneliusson O, Johnels B, Zetterberg H . Light subunit of neurofilament triplet protein in the cerebrospinal fluid after subthalamic nucleus stimulation for Parkinson's disease. Acta Neurol Scand. 2010; 124(3):206-10. DOI: 10.1111/j.1600-0404.2010.01451.x. View

Eriksdotter Jonhagen M, Nordberg A, Amberla K, Backman L, Ebendal T, Meyerson B . Intracerebroventricular infusion of nerve growth factor in three patients with Alzheimer's disease. Dement Geriatr Cogn Disord. 1998; 9(5):246-57. DOI: 10.1159/000017069. View

Ivics Z, Hackett P, Plasterk R, Izsvak Z . Molecular reconstruction of Sleeping Beauty, a Tc1-like transposon from fish, and its transposition in human cells. Cell. 1997; 91(4):501-10. DOI: 10.1016/s0092-8674(00)80436-5. View

Davis K, Mohs R . Enhancement of memory processes in Alzheimer's disease with multiple-dose intravenous physostigmine. Am J Psychiatry. 1982; 139(11):1421-4. DOI: 10.1176/ajp.139.11.1421. View

Ferreira D, Westman E, Eyjolfsdottir H, Almqvist P, Lind G, Linderoth B . Brain changes in Alzheimer's disease patients with implanted encapsulated cells releasing nerve growth factor. J Alzheimers Dis. 2014; 43(3):1059-72. DOI: 10.3233/JAD-141068. View

Rafii M, Baumann T, Bakay R, Ostrove J, Siffert J, Fleisher A . A phase1 study of stereotactic gene delivery of AAV2-NGF for Alzheimer's disease. Alzheimers Dement. 2014; 10(5):571-81. DOI: 10.1016/j.jalz.2013.09.004. View

Olsson A, Vanderstichele H, Andreasen N, De Meyer G, Wallin A, Holmberg B . Simultaneous measurement of beta-amyloid(1-42), total tau, and phosphorylated tau (Thr181) in cerebrospinal fluid by the xMAP technology. Clin Chem. 2004; 51(2):336-45. DOI: 10.1373/clinchem.2004.039347. View

McKelvey L, Shorten G, OKeeffe G . Nerve growth factor-mediated regulation of pain signalling and proposed new intervention strategies in clinical pain management. J Neurochem. 2012; 124(3):276-89. DOI: 10.1111/jnc.12093. View

Olson L, Nordberg A, von Holst H, Backman L, Ebendal T, Alafuzoff I . Nerve growth factor affects 11C-nicotine binding, blood flow, EEG, and verbal episodic memory in an Alzheimer patient (case report). J Neural Transm Park Dis Dement Sect. 1992; 4(1):79-95. DOI: 10.1007/BF02257624. View

10.

Eriksdotter-Jonhagen M, Linderoth B, Lind G, Aladellie L, Almkvist O, Andreasen N . Encapsulated cell biodelivery of nerve growth factor to the Basal forebrain in patients with Alzheimer's disease. Dement Geriatr Cogn Disord. 2012; 33(1):18-28. DOI: 10.1159/000336051. View

11.

Ammar I, Izsvak Z, Ivics Z . The Sleeping Beauty transposon toolbox. Methods Mol Biol. 2012; 859:229-40. DOI: 10.1007/978-1-61779-603-6_13. View

12.

Bartus R . On neurodegenerative diseases, models, and treatment strategies: lessons learned and lessons forgotten a generation following the cholinergic hypothesis. Exp Neurol. 2000; 163(2):495-529. DOI: 10.1006/exnr.2000.7397. View

13.

Mohs R, Knopman D, Petersen R, Ferris S, Ernesto C, Grundman M . Development of cognitive instruments for use in clinical trials of antidementia drugs: additions to the Alzheimer's Disease Assessment Scale that broaden its scope. The Alzheimer's Disease Cooperative Study. Alzheimer Dis Assoc Disord. 1997; 11 Suppl 2:S13-21. View

14.

Rosengren L, Karlsson J, Karlsson J, Persson L, Wikkelso C . Patients with amyotrophic lateral sclerosis and other neurodegenerative diseases have increased levels of neurofilament protein in CSF. J Neurochem. 1996; 67(5):2013-8. DOI: 10.1046/j.1471-4159.1996.67052013.x. View

15.

Lundqvist H, Nordberg A, Hartvig P, Langstrom B . (S)-(-)-[11C]nicotine binding assessed by PET: a dual tracer model evaluated in the rhesus monkey brain. Alzheimer Dis Assoc Disord. 1998; 12(3):238-46. DOI: 10.1097/00002093-199809000-00018. View

16.

Orive G, Santos E, Poncelet D, Hernandez R, Pedraz J, Wahlberg L . Cell encapsulation: technical and clinical advances. Trends Pharmacol Sci. 2015; 36(8):537-46. DOI: 10.1016/j.tips.2015.05.003. View

17.

Mates L, Chuah M, Belay E, Jerchow B, Manoj N, Acosta-Sanchez A . Molecular evolution of a novel hyperactive Sleeping Beauty transposase enables robust stable gene transfer in vertebrates. Nat Genet. 2009; 41(6):753-61. DOI: 10.1038/ng.343. View

18.

Orellana C, Ferreira D, Muehlboeck J, Mecocci P, Vellas B, Tsolaki M . Measuring Global Brain Atrophy with the Brain Volume/Cerebrospinal Fluid Index: Normative Values, Cut-Offs and Clinical Associations. Neurodegener Dis. 2016; 16(1-2):77-86. DOI: 10.1159/000442443. View

19.

Hao J, Ebendal T, Xu X, Wiesenfeld-Hallin Z, Eriksdotter Jonhagen M . Intracerebroventricular infusion of nerve growth factor induces pain-like response in rats. Neurosci Lett. 2000; 286(3):208-12. DOI: 10.1016/s0304-3940(00)01107-1. View

20.

Karami A, Eyjolfsdottir H, Vijayaraghavan S, Lind G, Almqvist P, Kadir A . Changes in CSF cholinergic biomarkers in response to cell therapy with NGF in patients with Alzheimer's disease. Alzheimers Dement. 2015; 11(11):1316-28. DOI: 10.1016/j.jalz.2014.11.008. View